Latest market price
17.47
-0.36-2.02%
TA
Loading chart...
Snapshot
| Index | — | P/E | — | EPS (ttm) | -1.65 | Insider Own | — | Shs Outstand | 61.14M | Perf Week | 4.86% |
| Market Cap | 1.07B | Forward P/E | — | EPS next Y | -2.67 | Insider Trans | -0.02% | Shs Float | 57.83M | Perf Month | 3.01% |
| Enterprise Value | 115.06M | PEG | — | EPS next Q | -0.47 | Short Float | 9.21% | Perf Quarter | 14.03% | ||
| Income | -102.00M | P/S | 44.50 | EPS this Y | — | Short Ratio | 6.30 | Perf Half Y | 21.83% | ||
| Sales | 24.00M | P/B | 1.15 | EPS next Y | — | ROA | -10.18% | Short Interest | 5.33M | Perf YTD | 26.59% |
| Book/sh | 15.18 | P/C | 1.10 | EPS next 5Y | — | ROE | -10.79% | 52W High | 35.34 -50.57% | Perf Year | -37.18% |
| Cash/sh | 15.88 | P/FCF | — | EPS past 3/5Y | — | ROIC | -15.11% | 52W Low | 12.12 44.14% | Perf 3Y | 181.77% |
| Dividend Est. | — | EV/EBITDA | — | Sales past 3/5Y | 3.57% — | Gross Margin | — | Volatility | 5.81% 5.25% | Perf 5Y | -23.24% |
| Dividend TTM | — | EV/Sales | 4.79 | EPS Y/Y TTM | — | Oper. Margin | -598.15% | ATR (14) | 0.87 | Perf 10Y | — |
| Dividend Ex-Date | — | Quick Ratio | 16.35 | Sales Y/Y TTM | — | Profit Margin | -427.47% | RSI (14) | 51.87 | Recom | 2.31 |
| Dividend Gr. 3/5Y | — | Current Ratio | 16.35 | EPS Q/Q | 36.36% | SMA20 | 0.89% | Beta | 2.42 | Target Price | 32.83 |
| Payout | 0.00% | Debt/Eq | 0.02 | Sales Q/Q | — | SMA50 | -0.72% | Rel Volume | 0.65 | Prev Close | 17.83 |
| Employees | 113 | LT Debt/Eq | 0.02 | Earnings | Nov 05 | SMA200 | 13.98% | Avg Volume | 831.35K | Price | 17.47 |
| IPO Date | Jun 11, 2021 | Option/Short | Yes / Yes | EPS/Sales Surpr. | -39.28% -46.17% | Net Debt/EBITDA | — | Volume | 540,011 | Change | -2.02% |
Analyst Ratings
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Aug-24-26 | Upgrade | Wolfe Research | Peer Perform → Outperform | $23 |
| Aug-07-26 | Reiterated | Stifel Nicolaus | $38 → $35 | |
| Aug-07-26 | Reiterated | Guggenheim | Buy | $55 |
| Jun-25-26 | Reiterated | Truist Financial | $26 | |
| May-11-26 | Reiterated | Evercore ISI | $23 → $22 | |
| May-08-26 | Reiterated | Wedbush | Outperform | $36 |
| Apr-20-26 | Downgrade | Barclays | Overweight → Underweight | $29 → $14 |
| Apr-15-26 | Downgrade | UBS | Buy → Neutral | $57 → $15 |
| Jan-20-26 | Downgrade | Clear Street | Buy → Hold | |
| Jan-16-26 | Reiterated | Piper Sandler | Overweight | $30 |
Latest News· Times ET
Oct-27-26
Oct-13-26
03:15AM
Oct-10-26
Oct-06-26
Oct-06-2606:15AM
Sep-30-26
Sep-30-2606:12AM
Sep-27-26
Sep-27-2611:07AM
Sep-18-26
Sep-18-2608:46AM
Sep-15-26
Sep-14-26
Sep-14-2608:00AM
Aug-24-26
Aug-24-2607:49AM
Aug-21-26
Aug-07-26
Company
Janux Therapeutics, Inc. is a biopharmaceutical company dedicated to developing innovative cancer therapies. The firm leverages its proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to create treatments designed to activate the body's T cells to fight tumors. Currently, Janux has several promising TRACTr product candidates in their early preclinical or discovery stages, which are engineered to target specific antigens such as prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. In addition to its TRACTr pipeline, the company is also developing a Tumor Activated Immunomodulator (TRACIr) — a costimulatory bispecific candidate designed to enhance T cell anti-tumor activity by engaging with programmed death-ligand 1 and CD28. Furthermore, a specific focus for their EGFR-TRACTr program is addressing epidermal growth factor receptor, a target prevalent in many cancer types and already a focus of numerous approved monoclonal antibody treatments. Janux Therapeutics, Inc. was founded in 2017 and is headquartered in La Jolla, California.
Ownership
Per-holder 13F data hasn't been ingested for this ticker yet.
Financial Statements
DataTimeframe
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 24 | 10 | 11 | 8 | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 0 | 2 | 2 | 2 | — | — | — | — | |
| Gross Profit | 24 | 8 | 9 | 6 | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 44 | 42 | 41 | 26 | — | — | — | — | |
| Research and Development | 125 | 126 | 68 | 55 | — | — | — | — | |
| Other Operating Expense | -2 | -2 | -2 | -2 | — | — | — | — | |
| Operating Income | -143 | -158 | -99 | -73 | — | — | — | — | |
| Interest Expense | 0 | 0 | 0 | 0 | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 41 | 44 | 30 | 15 | — | — | — | — | |
| Net Income Before Taxes | -102 | -114 | -69 | -58 | — | — | — | — | |
| Income Taxes | 0 | 0 | 0 | 0 | — | — | — | — | |
| Consolidated Net Income | -102 | -114 | -69 | -58 | — | — | — | — | |
| Net Income From Continuing Operations | -102 | -114 | -69 | -58 | — | — | — | — | |
| Net Income | -102 | -114 | -69 | -58 | — | — | — | — | |
| EPS (Recurring) | -1.65 | -1.83 | -1.28 | -1.32 | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | -1.65 | -1.83 | -1.28 | -1.32 | — | — | — | — | |
| EPS (Diluted) | -1.65 | -1.83 | -1.28 | -1.32 | — | — | — | — | |
| EBITDA | -101 | -112 | -67 | -56 | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | — | — | |
| Price To Sales Ratio | 45.86 | 85.56 | 262.83 | 59.02 | — | — | — | — | |
| Gross Margin | 100.00 | 80.00 | 81.82 | 75.00 | — | — | — | — | |
| Operating Margin | -595.83 | -1,580.00 | -900.00 | -912.50 | — | — | — | — | |
| Net Margin | -425.00 | -1,140.00 | -627.27 | -725.00 | — | — | — | — | |
| Shares Outstanding | 63 | 62 | 54 | 44 | — | — | — | — | |
| Market Capitalization | 1,101 | 856 | 2,891 | 472 | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — |
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
Insider Trading
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Campbell David Alan | President and CEO | Jul 08 '26 | Option Exercise | 4.21 | 7,000 | 29,470 | 388,582 | Jul 10 |
| Doyle Janeen Noel | Chief Corp. & Bus. Dev. Ofcr | Jun 02 '26 | Sale | 14.03 | 4,059 | 56,944 | 75,941 | Jun 04 |
| Dobek Maria | Vice President, Accounting | May 11 '26 | Sale | 14.17 | 2,038 | 28,878 | 32,270 | May 13 |
| Meyer Andrew Hollman | Chief Business Officer | Jan 02 '26 | Sale | 13.73 | 1,879 | 25,799 | 83,095 | Jan 02 |
| DiRaimondo Thomas | Chief Scientific Officer | Jan 02 '26 | Sale | 13.73 | 2,505 | 34,394 | 124,425 | Jan 02 |
| Campbell David Alan | President and CEO | Jan 02 '26 | Sale | 13.73 | 8,072 | 110,829 | 284,982 | Jan 02 |
| Winter Charles M. | Chief Technical Officer | Jan 02 '26 | Sale | 13.73 | 2,401 | 32,966 | 77,721 | Jan 02 |
| McIver Zachariah | Chief Medical Officer | Jan 02 '26 | Sale | 13.73 | 2,714 | 37,263 | 23,286 | Jan 02 |
| Dobek Maria | Vice President, Accounting | Jan 02 '26 | Sale | 13.73 | 1,462 | 20,073 | 15,373 | Jan 02 |
| Meyer Andrew Hollman | Chief Business Officer | Dec 01 '25 | Option Exercise | 10.59 | 3,333 | 35,296 | 88,307 | Dec 03 |
| Meyer Andrew Hollman | Chief Business Officer | Dec 01 '25 | Sale | 32.98 | 3,333 | 109,929 | 84,974 | Dec 03 |
| Meyer Andrew Hollman | Chief Business Officer | Nov 14 '25 | Option Exercise | 10.59 | 3,333 | 35,296 | 88,307 | Nov 14 |
| Meyer Andrew Hollman | Chief Business Officer | Nov 14 '25 | Sale | 30.00 | 3,333 | 99,990 | 84,974 | Nov 14 |
| Meyer Andrew Hollman | Chief Business Officer | Oct 28 '25 | Option Exercise | 6.76 | 16,665 | 112,689 | 98,804 | Oct 30 |
| Meyer Andrew Hollman | Chief Business Officer | Oct 28 '25 | Sale | 30.06 | 16,665 | 500,987 | 82,139 | Oct 30 |
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.